URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Daniel Lee Flynn net worth and biography

Daniel Flynn Biography and Net Worth

Insider of Deciphera Pharmaceuticals

Daniel L. Flynn, is Executive Vice President, Chief Scientific Officer and Founder of Deciphera Pharmaceuticals. Dr. Flynn founded Deciphera in 2003 and has more than 38 years of experience within the pharmaceutical and biotechnology industry. Before founding Deciphera, Dr. Flynn held senior roles with various biotechnology and pharmaceuticals companies, including Senior Director of Chemistry with Millennium Pharmaceuticals, Director, Medicinal Chemistry at Amgen Inc., and Director of Medicinal Chemistry, Combinatorial Chemistry and Research Fellow at Monsanto Company, G.D. Searle Unit. Dr. Flynn is currently Adjunct Professor of Medicinal Chemistry at the University of Kansas-Lawrence and has served as the National Chair for the Division of Medicinal Chemistry of the American Chemical Society. Dr. Flynn received both his B.S. in pharmacy and Ph.D. in medicinal chemistry from the University of Kansas, and he completed post-doctorate training in synthetic organic chemistry at Indiana University.

What is Daniel Lee Flynn's net worth?: The estimated net worth of Daniel Lee Flynn is at least $1.12 million as of January 17th, 2023. Dr. Flynn owns 43,695 shares of Deciphera Pharmaceuticals stock worth more than $1,118,155 as of December 16th. This net worth estimate does not reflect any other investments that Dr. Flynn may own. Learn More about Daniel Lee Flynn's net worth.
How do I contact Daniel Lee Flynn?: The corporate mailing address for Dr. Flynn and other Deciphera Pharmaceuticals executives is 200 SMITH STREET, Waltham MA, 02451. Deciphera Pharmaceuticals can also be reached via phone at (781) 209-6400 and via email at [email protected]. Learn More on Daniel Lee Flynn's contact information.
Has Daniel Lee Flynn been buying or selling shares of Deciphera Pharmaceuticals?: Daniel Lee Flynn has not been actively trading shares of Deciphera Pharmaceuticals within the last three months. Most recently, Daniel Lee Flynn sold 2,403 shares of the business's stock in a transaction on Tuesday, January 17th. The shares were sold at an average price of $21.24, for a transaction totalling $51,039.72. Following the completion of the sale, the insider now directly owns 43,695 shares of the company's stock, valued at $928,081.80. Learn More on Daniel Lee Flynn's trading history.
Who are Deciphera Pharmaceuticals' active insiders?: Deciphera Pharmaceuticals' insider roster includes James Bristol (Director), Daniel Flynn (Insider), Thomas Kelly (CFO), Matthew Sherman (EVP), and Michael Taylor (Director). Learn More on Deciphera Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Deciphera Pharmaceuticals?: In the last year, insiders at the sold shares 2 times. They sold a total of 4,059 shares worth more than $58,733.73. The most recent insider tranaction occured on January, 16th when EVP Matthew L Sherman sold 2,435 shares worth more than $35,234.45. Insiders at Deciphera Pharmaceuticals own 4.7% of the company. Learn More about insider trades at Deciphera Pharmaceuticals.
Information on this page was last updated on 1/16/2024.

Daniel Lee Flynn Insider Trading History at Deciphera Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
1/17/2023	Sell	2,403	$21.24	$51,039.72	43,695
2/16/2022	Sell	1,366	$9.05	$12,362.30
11/11/2019	Sell	152,927	$48.91	$7,479,659.57
10/28/2019	Sell	29,820	$44.34	$1,322,218.80
8/13/2019	Sell	148,107	$40.92	$6,060,538.44
1/16/2019	Sell	152,629	$26.00	$3,968,354.00
1/11/2019	Sell	300	$26.00	$7,800.00

Daniel Lee Flynn Buying and Selling Activity at Deciphera Pharmaceuticals

Deciphera Pharmaceuticals Company Overview

Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage. Deciphera Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.

Today's Range

Now: $25.59

$25.59

50 Day Range

MA: $25.59

$25.55

$25.59

2 Week Range

Now: $25.59

$9.90

$25.61

Volume

600 shs

Average Volume

1,292,551 shs

Market Capitalization

$2.21 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.19